about
In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine.Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and childrenAnti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and childrenAddition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]Borreliacidal activity of Borrelia metal transporter A (BmtA) binding small molecules by manganese transport inhibition.The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis.The employment of leukotriene antagonists in cutaneous diseases belonging to allergological fieldAddition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma.Effect of antihistamine as an adjuvant treatment of isotretinoin in acne: a randomized, controlled comparative study.Prevalence of desloratadine poor metabolizer phenotype in healthy Jordanian males.Next generation antihistamines: therapeutic rationale, accomplishments and advances.Therapeutic points of intervention and clinical implications: role of desloratadine.Chronic urticaria: impact of allergic inflammation.Impact and modulation of nasal obstruction.Advances in allergy management.Emerging safety issues regarding long-term usage of H(1)receptor antagonists.Anti-inflammatory properties of desloratadine.Antihistamines in dermatology.Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety.A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhinoconjunctivitis: a randomized, double-blind, placebo-controlled studySafety evaluation of desloratadine in allergic rhinitis.Synthesis and biological evaluation of substituted desloratadines as potent arginine vasopressin V2 receptor antagonists.Effect of desloratadine on patients with allergic rhinitis and exercise-induced bronchoconstriction: a placebo controlled study.Rhinitis symptoms and quality of life in patients with chronic perennial rhinitis treated with desloratadine.Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria.Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms.Acute cholestasis related to desloratidine.Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring.Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis.Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure.Inhibition of cold urticaria by desloratadine.Improvements in simulated real-world relevant performance for patients with seasonal allergic rhinitis: impact of desloratadine.Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study.Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis.Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers.The effect of desloratadine on eosinophil/basophil progenitors and other inflammatory markers in seasonal allergic rhinitis: a placebo-controlled randomized study.Effectiveness and Safety of the Combination of the Traditional Chinese Medicine Prescription Jade Screen and Desloratadine in the Treatment of Chronic Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Computational and experimental investigation of DNA repair protein photolyase interactions with low molecular weight drugs.Prevalence of Desloratadine Slow-metabolizer Phenotype and Food-dependent Pharmacokinetics of Desloratadine in Healthy Chinese Volunteers.
P2860
Q21262021-5B4BF0D2-ACAE-45CD-B078-5F59FB65AD4CQ24197682-CEAC4778-5794-459F-9A4A-4CC8E0A4D62EQ24247433-EA3AB50C-E7D7-454B-8B7D-21AFA53FEF5DQ24247489-92107DBE-2659-41D1-B71A-0BBD7D061B67Q24799644-5E430D77-B782-4A69-9059-D0359B8DBCF7Q30372052-7986907C-CDA5-4117-AFFE-0E02F845FA49Q30498416-E8B4C769-936C-491E-9241-9F2199F5798BQ34141112-7BEEEAE0-D919-4A51-B501-2E11A4AE4E3DQ34424227-7E5A33F2-929F-448C-AA90-4CBB39629018Q34431787-569B414E-FA11-4EE5-A576-03BBD35FAB27Q34635320-EF744C78-A6DB-499E-9F6A-172D7AE0FE22Q34660867-69876635-409C-4887-A71D-B9C8939432FEQ35030805-C154BD2C-107A-4F10-90C2-B65A0F61FACBQ35030810-7AE3D631-CF53-4FA2-BA87-7AE59F86E2EDQ35030815-5B8405E8-46A2-4CF7-BF50-5381CA81D833Q35030819-D6367F99-0BC8-4939-8733-E3DBE5AF3E28Q35194475-A83C7C71-1138-471D-8CC6-3027BA7A7F0CQ35878377-83046254-BADC-45BB-9E3F-5B96E837B62AQ36193211-F549E66B-BCED-4B98-9729-3B87D1C2DE8EQ36407261-32F60620-17F6-4B27-AB80-1F4B83AE93FCQ36638677-54DED084-EF72-41A2-AB9E-1DFD58F84401Q38097964-7D6DB357-8588-45B2-B393-DC084A80CD9FQ39021158-9EE0A8DC-8752-44A0-8618-414BE099434EQ39306892-A8E67358-6395-40CE-84B4-8029924F8DA4Q39332763-89D5361A-FFAB-4B27-AAC4-E55C3AF96CADQ39354410-A3330681-8861-4657-A093-DC6F911BA098Q39979447-1639BE51-9131-49D1-A9D8-68806B620AC8Q42726753-7B0F1F24-01F7-43D8-A631-C8C8449871C5Q44051767-C588AE09-7AA5-4A41-9CCF-05849EA3A2DBQ44173557-0724031C-64D5-4445-A4E8-A01C6EA4BDE7Q44447881-3CC7F8C0-5BF7-4548-9B89-459007A4B240Q44750212-6ABF6D47-73D0-4EEA-AE55-3E00FC14BFB9Q44789691-7CF0DE46-0EDB-4249-B50E-3708303C9C4CQ44834103-8D612B4C-1117-4533-B9D3-134025971ED0Q44841368-4D14340A-38AF-49A3-9373-4604556EADCFQ45148117-7E5426FD-9855-4F9F-903A-199B21EA4E32Q46740448-A3DEB32E-CAF8-4113-A694-29FF20EDDEDCQ47149312-A1CC7869-3DBC-4F98-99A6-23362ECD8D3EQ47236264-98ECF940-B840-4CC5-8043-FEF7C5C40B94Q51295892-3603E8FC-BB5E-4BD0-85AC-F342C63E1836
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Desloratadine: A new, nonsedating, oral antihistamine.
@ast
Desloratadine: A new, nonsedating, oral antihistamine.
@en
Desloratadine: A new, nonsedating, oral antihistamine.
@nl
type
label
Desloratadine: A new, nonsedating, oral antihistamine.
@ast
Desloratadine: A new, nonsedating, oral antihistamine.
@en
Desloratadine: A new, nonsedating, oral antihistamine.
@nl
prefLabel
Desloratadine: A new, nonsedating, oral antihistamine.
@ast
Desloratadine: A new, nonsedating, oral antihistamine.
@en
Desloratadine: A new, nonsedating, oral antihistamine.
@nl
P356
P1476
Desloratadine: A new, nonsedating, oral antihistamine.
@en
P2093
P304
P356
10.1067/MAI.2001.114239
P407
P577
2001-04-01T00:00:00Z